Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 7/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PER2 | O15055 | 3/20 | 0.34 |
| ▸ | CRY1 | Q16526 | 3/20 | 0.34 |
| ▸ | CRY2 | Q49AN0 | 3/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | PFKFB4 | Q16877 | 1/20 | 0.32 |
| ▸ | GHSR | Q92847 | 1/20 | 0.31 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3692931 | 0.90 | CMA1 (0.35) | CMA1LMNAMEN1KMT2APER2 | |
| SCHEMBL3686964 | 0.89 | NPSR1 (0.45) | CMA1NPSR1L3MBTL1PFKFB4SLC2A1 | |
| SCHEMBL3685852 | 0.85 | CMA1 (0.38) | CMA1LMNAMEN1KMT2ANPSR1 | |
| SCHEMBL13509407 | 0.85 | CMA1 (0.35) | CMA1LMNAMEN1KMT2APER2 | |
| SCHEMBL6269450 | 0.83 | CMA1 (0.38) | CMA1LMNAMEN1KMT2APER2 | |
| SCHEMBL13508348 | 0.81 | PER2 (0.43) | CMA1LMNAMEN1KMT2APER2 | |
| SCHEMBL13508284 | 0.80 | PER2 (0.48) | CMA1PER2CRY1CRY2PFKFB4 | |
| SCHEMBL3690605 | 0.79 | NPSR1 (0.45) | CMA1NPSR1L3MBTL1PFKFB4SLC2A1 | |
| SCHEMBL3687739 | 0.76 | SLC2A1 (0.44) | CMA1NPSR1L3MBTL1PFKFB4SLC2A1 | |
| SCHEMBL3687742 | 0.76 | SLC2A1 (0.44) | CMA1NPSR1L3MBTL1PFKFB4SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655641-B2 | Sulfonamide derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-7655641-B2 | Sulfonamide derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| EP-1597248-B1 | SULFONAMIDE DERIVATIVES AS PPAR MODULATORS | LILLY CO ELI (US) | 2007-12-26 | — | — | EP | disclosed |
| US-20060217433-A1 | Sulfonamide derivatives as ppar modulators | ELI LILLY AND COMPANY (US) | 2006-09-28 | — | — | US | disclosed |
| EP-1597248-A2 | SULFONAMIDE DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004073606-A2 | SULFONAMIDE DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217433-A1 | Sulfonamide derivatives as ppar modulators | PPARD, PPARA, PPARG | CMA1 4529/4885LMNA 3056/4885MEN1 4858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.